
Stocks Market
T2S Group Commits 60 Million Dirhams to New Radiopharmaceutical Production Facility in Fez
Morocco's T2S Group is advancing its expansion strategy with a 60 million dirham investment in a second radiopharmaceutical production facility through its subsidiary Cyclopharma. The Fez-based plant, which broke ground in October 2026, represents a strategic move to enhance nuclear medicine capabilities across Morocco's northern regions. Scheduled for commissioning in Q2 2028, the facility will address critical healthcare needs in oncology, cardiology, and neurology diagnostics.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
T2S Group, listed on the Casablanca Stock Exchange, is executing its post-IPO investment roadmap with the construction of a state-of-the-art radiopharmaceutical manufacturing unit in Fez. The 60 million dirham project, managed through subsidiary Cyclopharma SA, marks a significant milestone in Morocco's nuclear medicine infrastructure development.
Strategic Expansion Beyond Casablanca
Construction activities commenced on October 1, 2026, establishing Cyclopharma's second industrial site after its existing Bouskoura-Oulad Saleh facility near Casablanca. The new installation is designed to strengthen domestic production capacity for specialized medications used in nuclear medicine applications, particularly for diagnostic and monitoring purposes in oncology, cardiology, and neurology.
Geographic Coverage and Time-Sensitive Logistics
The Fez location addresses a critical operational challenge in radiopharmaceutical distribution. These medications often have extremely short radioactive half-lives, making proximity to healthcare facilities essential. By establishing production capabilities in Fez, T2S Group aims to improve service delivery to the Fez-Meknès and Oriental regions, reducing transportation time and expanding access to nuclear medicine diagnostics.
Advanced Technical Infrastructure
The planned facility features sophisticated technical specifications across multiple levels:
- Two basement levels for critical infrastructure
- Ground floor operational areas
- Three additional floors for support functions
- Reinforced bunker housing a cyclotron for radioisotope production
- Dedicated manufacturing laboratories
- Quality control and radiological monitoring systems
- Secure storage facilities
- Radioactive waste management infrastructure
Timeline and Regulatory Pathway
T2S Group targets operational readiness for the second quarter of 2028, contingent upon construction progress and securing necessary regulatory approvals from Moroccan authorities. The timeline reflects the complex nature of nuclear medicine facility licensing and the stringent safety requirements for radiopharmaceutical production.
Multi-Site Industrial Strategy
This investment aligns with T2S Group's multi-site industrial model announced during its July 2026 initial public offering. Expanding radiopharmaceutical production capacity represents a core growth pillar in the company's industrial development framework, positioning Morocco as a regional hub for nuclear medicine manufacturing.
The Fez project demonstrates T2S Group's commitment to strengthening Morocco's healthcare infrastructure while capitalizing on the growing demand for advanced diagnostic capabilities across North Africa.